Browse All
Displaying 1 - 2 of 2
Author:Cohen, Jeffrey Hauser, Stephen Cross, Anne Winthrop, Kevin Wiendl, Heinz Nicholas, Jacqueline Meuth, Sven Giacomini, Paul Sacca, Francesco Zielman, Ronald Das Gupta, Ayan Hu, Xixi Sullivan, Roseanne DeLasHeras, Virginia Kappos, Ludwig
Session Name:P8: MS Therapeutics 2
Topic:MS and Inflammatory Disease
Program Number:P8.004
Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR University of Muenster, Muenster, Germany, Muenster, Germany OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada NSRO Department, University “Federico II” of Naples, Naples, Italy, Napoli, Italy Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland
Author:Bove, Riley Pia Amato, Maria Dobson, Ruth M. Krysko, Kristen Stoll, Sharon Vukusic, Sandra Yamout, Bassem Zielman, Ronald Krishna Gummuluri, Swetha Jehl, Valentine Schulze Topphoff, Ulf Sullivan, Roseanne Fantaccini, Simone Hellwig, Kerstin
Session Name:P9: MS Special Populations
Program Number:P9.014
Author Institution:UCSF Weill Institute for Neuroscience, University of California San Francisco, San Francisco, California, USA, Berkeley, CA Department NEUROFARBA, University of Florence, Florence, Italy IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy, Florence, Italy Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom, London, United Kingdom Division of Neurology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ontario, Canada, Toronto, ON, Canada Department of Neurology, Yale University, New Haven, Connecticut, USA, New Haven, CT Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques, Lyon, France Université Claude Bernard Lyon 1, Villeurbanne, France, BRON Cedex, France American University of Beirut Medical Center, Beirut, Lebanon Harley Street Medical Centre, Abu Dhabi, UAE, Beirut, Lebanon Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India Novartis Pharma A.G. Basel, Switzerland, Basel, Switzerland Novartis Pharma GmbH, Germany, Nuernberg, Germany Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ Novartis Pharma A.G. Basel, Switzerland, Binningen, Switzerland St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany, Bochum, Germany
